APOA1 and amyotrophic lateral sclerosis: Based on reported positive ApoA1 effects to reduce EC-induced cytotoxicity (Svensson et al., 2017) or carotid artery inflammation (Puranik et al., 2008), the current study was designed to determine whether ApoA1 alleviates injury to ECs under a pathologic in vitro environmental condition reminiscent of ALS.